KK
ACAD icon

KLP Kapitalforvaltning’s Acadia Pharmaceuticals ACAD Stock Holding History

KLP Kapitalforvaltning’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$660K Hold
26,100
– – ﹤0.01% 1376
2026
Q1 		$581K Sell
26,100
-18,400
-41% -$440K ﹤0.01% 1358
2025
Q4 		$1.19M Hold
44,500
– – ﹤0.01% 944
2025
Q3 		$950K Buy
44,500
+21,600
+94% +$511K ﹤0.01% 1061
2025
Q2 		$494K Buy
22,900
+2,400
+12% +$44.6K ﹤0.01% 1374
2025
Q1 		$341K Hold
20,500
– – ﹤0.01% 1503
2024
Q4 		$376K Buy
+20,500
New +$331K ﹤0.01% 1529

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

KLP Kapitalforvaltning's ACAD Position: Q2 2026 in Review

KLP Kapitalforvaltning held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 26,100 shares worth $660K. The position accounts for ﹤0.01% of the portfolio, ranked #1376.

KLP Kapitalforvaltning first reported a position in ACAD in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.19M in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • KLP Kapitalforvaltning held 26,100 shares of Acadia Pharmaceuticals worth $660K as of Q2 2026.
  • KLP Kapitalforvaltning left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1376 holding.
  • KLP Kapitalforvaltning first reported a position in Acadia Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • KLP Kapitalforvaltning's Acadia Pharmaceuticals position peaked at $1.19M in Q4 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.